EMGALITY 120 mg/mL

EMGALITY 120 mg/mL is a subcutaneous injection solution containing galcanezumab-gnlm. It is used for the prevention of migraine headaches. This medication is manufactured by Eli Lilly and Company in the USA.

EMGALITY 120 mg/mL is primarily used for the prevention of migraine headaches. Migraines are severe headaches that can cause throbbing pain, nausea, and sensitivity to light and sound. This medication is designed to reduce the frequency and severity of migraine episodes. People who experience frequent migraines may find relief with this treatment option.

Common effects of EMGALITY 120 mg/mL may include injection site reactions, such as redness, swelling, or itching. Some users may also experience fatigue, upper respiratory infections, or constipation. These effects vary among individuals and are not experienced by everyone who uses the medication.

EMGALITY 120 mg/mL should be handled with care. The solution is meant for subcutaneous use only and should not be injected into a vein or muscle. It is important to follow proper injection techniques and dispose of used syringes safely. Always consult a healthcare provider before starting any new medication.

EMGALITY 120 mg/mL may interact with other medications, including those that affect the immune system or blood clotting. It is important to inform your healthcare provider about all medications you are taking, including over-the-counter drugs and supplements. Alcohol consumption should also be discussed with a healthcare provider.